Pembrolizumab Earns Traditional Approval in HER2+ Gastric Cancer

Merck's pembrolizumab (Keytruda) converted from accelerated to traditional FDA approval on March 19, 2025, for first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing PD-L1 (CPS ≥1). The conversion, grounded in mature KEYNOTE-811 data, locks in a three-drug combination regimen -- pembrolizumab plus trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy -- that carries direct implications for manufacturing scheduling, supply chain coordination, and batch release sequencing across multiple biologic and small-molecule platforms.

KEYNOTE-811 (NCT03615326) enrolled 698 patients in a multicenter, randomized, double-blind, placebo-controlled design. Of those, 594 patients (85%) had tumors with PD-L1 CPS ≥1, confirmed using the PD-L1 IHC 22C3 pharmDx companion diagnostic kit. In that biomarker-defined population, median progression-free survival reached 10.9 months in the pembrolizumab arm versus 7.3 months in the placebo arm (HR 0.72; 95% CI: 0.60, 0.87). Median overall survival was 20.1 months versus 15.7 months (HR 0.79; 95% CI: 0.66, 0.95). Overall response rate was 73% versus 58%, with median duration of response of 11.3 months versus 9.6 months. The adverse reaction profile was consistent with the established pembrolizumab safety profile.

For QA directors and plant heads, the approved dosing schedule -- 200 mg every three weeks or 400 mg every six weeks -- must now be coordinated against trastuzumab and chemotherapy supply cycles under GMP-compliant conditions. Contract manufacturers supporting oncology combination regimens face increasing pressure to align release testing timelines, cold-chain logistics, and 21 CFR Part 211 documentation across biologics and cytotoxic small molecules simultaneously. The companion diagnostic requirement (IHC 22C3 pharmDx) adds a parallel quality system dependency that supply chain leads will need to factor into patient access planning.

The application carried orphan drug designation and was reviewed using the FDA's Assessment Aid, a voluntary applicant submission tool. The program also aligned with Project FrontRunner, an FDA Oncology Center of Excellence initiative encouraging earlier-line development for advanced or metastatic cancers. Pembrolizumab's original accelerated approval for this indication was granted May 5, 2021, based on interim KEYNOTE-811 data. Full prescribing information is available on Drugs@FDA.